TNF抑制剂在成人幼年特发性关节炎中的有效性与安全性
基于英国风湿病学会生物制剂注册库,纳入443例成年起病前JIA患者首次启用TNFi,1年后各疾病模式活动度均改善;严重感染IR 22.3/1000人年,恶性肿瘤率低于RA队列,葡萄膜炎率更高,严重感染风险低于RA(HR 0.5)。
要点
- 成人JIA首次启用TNFi后1年,各疾病模式疾病活动度均改善。
- 严重感染IR 22.3/1000人年,恶性肿瘤率低于加权RA队列。
- 葡萄膜炎发生率显著高于RA队列,需关注眼部监测。
核心结论
- 成人JIA患者首次启用TNFi治疗1年后各疾病模式疾病活动度均改善,提示TNFi在该人群有效。
研究设计与样本
- 来自英国风湿病学会生物制剂注册库,纳入443例关节炎起病<16岁、成年后首次启用TNFi的JIA患者。
- 按疾病模式描述治疗1年后DAS28和HAQ结局,计算不良事件每1000人年发生率。
- 将多关节型JIA患者与按年龄和性别加权的RA队列进行比较。
主要发现
- 443例成人JIA首次启用TNFi后1年内所有疾病活动度指标均改善。
- 报告58例首次严重感染(IR 22.3/1000人年)、4例心血管事件(IR 1.4/1000人年)、11例葡萄膜炎事件(IR 4.0/1000人年)和16例恶性肿瘤(IR 3.9/1000人年)。
- 与加权RA队列相比,疾病活动度改善相似,恶性肿瘤率更低,葡萄膜炎率更高。
- 粗发生率相似,但JIA患者严重感染风险更低(HR 0.5,95%CI 0.3-0.9)。
关键数值与推荐
- 严重感染IR 22.3/1000人年;心血管事件IR 1.4/1000人年;葡萄膜炎IR 4.0/1000人年;恶性肿瘤IR 3.9/1000人年。
- JIA患者严重感染风险HR 0.5(95%CI 0.3-0.9),对照为加权RA队列。
临床怎么用
- 成人JIA首次启用TNFi可有效改善1年疾病活动度。
- 治疗中需关注严重感染,并与RA患者相比注意更高的葡萄膜炎风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Many children with juvenile idiopathic arthritis (JIA) continue to have active disease into adulthood. Adults with JIA are a heterogeneous group, and the effects of tumour necrosis factor inhibitor (TNFi) therapies are not well described. This analysis aims to describe treatment outcomes among patients with JIA starting TNFi for the first time in adulthood. METHODS: Patients with arthritis onset <16 years starting their first TNFi therapy were identified from the British Society of Rheumatology Biologics Register. Disease activity outcomes (using 28-joint Disease Activity Score (DAS28) and Health Assessment Questionnaire (HAQ)) are presented at 1 year after start of therapy according to disease pattern. Incidence rates (IR) of adverse events per 1000 person-years (pyrs) were calculated. Outcomes in patients with polyarticular JIA were compared with a cohort (weighted for age and gender) of patients with rheumatoid arthritis (RA). RESULTS: In 443 adults with JIA starting a first TNFi, disease activity over 1 year improved across all measures. There were 58 first serious infections (IR 22.3/1000 pyrs); 4 cardiovascular events (IR 1.4/1000 pyrs); 11 uveitis events (IR 4.0/1000 pyrs) and 16 malignancies (IR 3.9/1000 pyrs). Compared with the weighted RA cohort, disease activity improvement was similar; malignancy rates were lower and uveitis rates much higher. While crude IR were similar, JIA patients had a lower risk of serious infection (HR 0.5 (95% CI 0.3 to 0.9)). CONCLUSIONS: This is the largest study to describe disease activity and safety outcomes in adults with JIA receiving TNFi. Disease activity improved after 1 year in all disease patterns, suggesting TNFi is an effective therapy in this population.
引用
- Kearsley-Fleet L, McErlane F, Foster HE, et al. Effectiveness and safety of TNF inhibitors in adults with juvenile idiopathic arthritis. RMD Open. 2016. PMID: 27843575
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。